Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas P Restifo

Showing results (61-70 of 260) with videos related to

Pageof 26
Sort By:
Cancer Research|January 21, 2006
The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumorLeroy N Hwang, Zhiya Yu, Douglas C Palmer, et al.
Nature Reviews. Immunology|April 20, 2006
Adoptive immunotherapy for cancer: building on successLuca Gattinoni, Daniel J Powell, Steven A Rosenberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2005
Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapyChien-Chung Chang, Michael Campoli, Nicholas P Restifo, et al.
Trends in Immunology|March 26, 2014
Reprogramming antitumor immunityJoseph G Crompton, David Clever, Raul Vizcardo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 15, 2005
Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cellsChristian S Hinrichs, Douglas C Palmer, Steven A Rosenberg, et al.
Vaccine|May 27, 2006
Type I Interferons are essential for the efficacy of replicase-based DNA vaccinesWolfgang W Leitner, Elke S Bergmann-Leitner, Leroy N Hwang, et al.
Blood|July 16, 2010
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsJames N Kochenderfer, Zhiya Yu, Dorina Frasheri, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2001
Intensity of the vaccine-elicited immune response determines tumor clearanceAinhoa Perez-Diez, Paul J Spiess, Nicholas P Restifo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2005
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine designOleg Y Borbulevych, Tiffany K Baxter, Zhiya Yu, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumorsWillem W Overwijk, Ena Wang, Francesco M Marincola, et al.
Pageof 26

Showing results (61-70 of 260) with videos related to

Sort By:
Pageof 26
Cancer Research|January 21, 2006
The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumorLeroy N Hwang, Zhiya Yu, Douglas C Palmer, et al.
Nature Reviews. Immunology|April 20, 2006
Adoptive immunotherapy for cancer: building on successLuca Gattinoni, Daniel J Powell, Steven A Rosenberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2005
Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapyChien-Chung Chang, Michael Campoli, Nicholas P Restifo, et al.
Trends in Immunology|March 26, 2014
Reprogramming antitumor immunityJoseph G Crompton, David Clever, Raul Vizcardo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 15, 2005
Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cellsChristian S Hinrichs, Douglas C Palmer, Steven A Rosenberg, et al.
Vaccine|May 27, 2006
Type I Interferons are essential for the efficacy of replicase-based DNA vaccinesWolfgang W Leitner, Elke S Bergmann-Leitner, Leroy N Hwang, et al.
Blood|July 16, 2010
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsJames N Kochenderfer, Zhiya Yu, Dorina Frasheri, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2001
Intensity of the vaccine-elicited immune response determines tumor clearanceAinhoa Perez-Diez, Paul J Spiess, Nicholas P Restifo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2005
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine designOleg Y Borbulevych, Tiffany K Baxter, Zhiya Yu, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumorsWillem W Overwijk, Ena Wang, Francesco M Marincola, et al.
Pageof 26